Peter Verheesen

Company: ArgenX

Job title: Research Fellow

Seminars:

FcRn Inhibition As A Novel Approach For Treating Autoimmune Blistering Disorders 10:30 am

Investigating Efgartigimod as a human IgG1 Fc fragment which outcompetes endogenous IgG from binding to FcRn thereby decreasing its half-life and circulating concentration. Relaying a recent phase 2 study in patients with mild to moderate pemphigus, an autoimmune blistering disorder, where efgartigimod has demonstrated an early onset of disease control allowing for early corticosteroid tapering…Read more

day: Day Two